Page 3 - Genitourinary Malignancies Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genitourinary Malignancies Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genitourinary Malignancies Program Today - Breaking & Trending Today

Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive pr

Published: February 23, 2022

Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer Results from the Phase III ARASENS trial evaluating darolutamide plus androgen deprivation therapy (ADT) and docetaxel showed a statistically signif...

Source: pharmiweb.com

Adding Darolutamide: New SOC for Metastatic Prostate Cancer

Published: February 19, 2022

Darolutamide added onto ADT and docetaxel could be a new standard of care for men with metastatic hormone-sensitive prostate cancer.

Source: medscape.com

Investegate |Orion Oyj Announcements | Orion Oyj: Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer

Published: February 17, 2022

Investegate announcements from Orion Oyj, Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer

Source: investegate.co.uk